<DOC>
	<DOCNO>NCT00905138</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single ascending ( SAD ) multiple ( MD ) oral dose GLPG0259 compare placebo . Also , pharmacokinetics ( PK ) pharmacodynamics ( PD ) GLPG0259 single multiple oral administration evaluate , , applicable , maximum tolerate dose determine .</brief_summary>
	<brief_title>First-in-Human Single Ascending Multiple Dose GLPG0259</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>healthy male , age 1850 year BMI 1830 kg/mÂ² , inclusive . significantly abnormal platelet function coagulopathy smoke drug alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>